Skip to main content
8 March 2021
Last updated:
Monday 8 March 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
    • News
    • Appointments
    • Events
  • About MedNous
  • Research Directory
  • Contact Us

News

GSK partners with Sosei Group

Monday 21 December 2020
Country

Japan

Japan-based Sosei Group Corp has entered a global collaboration and licencing agreement with GlaxoSmithKline Plc to discover small molecule agonists of a G protein-coupled receptor (GPCR) associated with inflammatory bowel disease and other gastrointestinal immune disorders. It will use technology developed by Heptares Therapeutics, a UK company it acquired in 2015. The deal is the newest collaboration for Sosei, which is using the Heptares’ structure-based drug design platform to grow its business.

Read more

EUA for Moderna Covid-19 vaccine

Saturday 19 December 2020
Country

United States

The US Food and Drug Administration has issued an emergency use authorisation to Moderna Inc for a vaccine for Covid-19 following trial data showing it was 94.1% effective in preventing the disease. The decision comes just a week after the agency issued an emergency authorisation for a vaccine developed by BioNTech SE and its partner Pfizer Inc. Both vaccines are based on messenger RNA (mRNA), a technology never before used in a human vaccine. The two vaccines work by instructing cells in the body to make copies of the SARS-CoV-2 spike protein.

Read more

No US filing for filgotinib in RA

Wednesday 16 December 2020
Country

Belgium

Gilead Sciences Inc and Galapagos NV have dropped plans to make a new submission in the US for their small molecule drug Jyseleca (filgotinib) in rheumatoid arthritis (RA) following a meeting with the Food and Drug Administration. The parties discussed the points raised in the agency’s complete response letter in August in which it refused to approve the drug because of concerns about its benefit/risk profile at a dose of 200 mg.

Read more

Hemab launched in Denmark

Tuesday 15 December 2020

Hemab ApS, a new company led by scientists with experience in haemophilia drug development, has been launched in Copenhagen, Denmark to develop bispecific antibodies for treating rare bleeding disorders. The company was incubated by Novo Seeds, the early-stage investment arm of Novo Holdings A/S. The size of the seed funding was not disclosed.

Read more

AZ to acquire Alexion

Monday 14 December 2020
Country

United Kingdom

AstraZeneca Plc is to acquire the US specialty pharmaceutical company Alexion Pharmaceuticals Inc for $39 billion – at once giving it five marketed drugs and more than 20 development programmes for rare diseases and immunology. The cash and share offer will be paid in part with an underwritten bridge-financing facility. The transaction is expected to close in the third quarter of 2021 and be immediately earnings accretive.

Read more

Evotec partners to develop exosomes

Saturday 12 December 2020
Country

Germany

Evotec SE and the service group Sartorius AG are taking a controlling stake in a new German company, Curexsys GmbH, in order to support the emerging science of therapeutic exosomes. Exosomes are small vesicles that transfer proteins and nucleic acids from one cell to another. Researchers have shown that exosomes can be engineered to contain drugs, something that is being exploited by a growing number of biotech companies.

Read more

FDA issues EUA for Pfizer/BioNTech vaccine

Saturday 12 December 2020
Country

United States

The US has become the second western country to give an emergency use authorisation to a Covid-19 vaccine developed by BioNTech SE in partnership with Pfizer Inc. The vaccine, BNT162b2, is based on messenger RNA (mRNA), a technology never before used in a human vaccine. It was given an emergency authorisation by the Food and Drug Administration on 11 December for individuals 16 years and over.

Read more

Delay in Sanofi and GSK Covid-19 vaccine

Friday 11 December 2020

Sanofi SA and its partner GlaxoSmithKline Plc are to test a new antigen formulation for their  Covid-19 vaccine in order to generate a better response from older adults. Assuming all data are positive, the vaccine would be available in the 2021 fourth quarter rather than mid-2021, the companies announced on 11 December 2020.

Read more

Boehringer to acquire NBE-Therapeutics

Friday 11 December 2020
Country

Germany

Boehringer Ingelheim GmbH is to pay €1.18 billion to acquire NBE-Therapeutics GmbH, a Swiss developer of antibody-drug conjugates (ADCs), in order to expand its portfolio of drugs targeting difficult-to-treat solid tumours. NBE-Therapeutics’ lead compound NBE-002 is currently in Phase 1 clinical studies for triple negative breast cancer, an aggressive form of breast cancer with limited treatment options.

Read more

Forbion raises €460 million for new fund

Wednesday 9 December 2020
Country

Netherlands

Forbion Capital Partners of the Netherlands has secured €460 million for an oversubscribed fifth fund, the proceeds of which will be used to build a portfolio of 15 companies developing new medical therapeutics. About 80% of the investments are expected to be made in Europe, with the balance targeting assets in North America.

Read more

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page next ›
  • Last page last »

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Microbiotica expands management team
Wednesday February 10 2021
Philippe Dro joins Scenic Biotech as independent chairman
Wednesday February 10 2021
NOXXON announces senior appointment to its new advisory board
Wednesday February 10 2021
Wendy Levin joins Biofidelity as chief medical officer
Wednesday February 10 2021
VarmX appoints Gerard Short as chief medical officer
Wednesday February 10 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.